BCL2 and cancer: BH3 mimetics are small-molecule synthetic inhibitors of Bcl-2 and Bcl-xL, specifically developed as anti-cancer agents.7 They mimic activated BH3-only proteins by disrupting the heterodimerisation of anti- and pro-apoptotic Bcl-2 family members, and thus sensitising cells to apoptosis.